Zarator 10 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 10 mg filmovertrukne tabletter

upjohn eesv - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 10 mg

Zarator 20 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 20 mg filmovertrukne tabletter

upjohn eesv - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 20 mg

Zarator 40 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 40 mg filmovertrukne tabletter

upjohn eesv - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 40 mg

Zarator 80 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 80 mg filmovertrukne tabletter

upjohn eesv - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 80 mg

Zarator 10 mg tyggetabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 10 mg tyggetabletter

upjohn eesv - atorvastatincalcium (trihydrat) - tyggetabletter - 10 mg

Zarator 20 mg tyggetabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

zarator 20 mg tyggetabletter

upjohn eesv - atorvastatincalcium (trihydrat) - tyggetabletter - 20 mg

Atorvastatin "Aristo" 10 mg filmovertrukne tabletter Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

atorvastatin "aristo" 10 mg filmovertrukne tabletter

aristo pharma gmbh - atorvastatincalcium (trihydrat) - filmovertrukne tabletter - 10 mg

Calquence Europese Unie - Deens - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.